A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells

Chem Commun (Camb). 2015 May 21;51(41):8626-9. doi: 10.1039/c5cc01952d.

Abstract

A targeted and image-guided platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics was designed for real-time and in situ drug activation monitoring in cancer cells as well as combinational photodynamic-chemotherapy against cisplatin resistant cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / chemistry
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cisplatin / chemistry
  • Cisplatin / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Screening Assays, Antitumor
  • HEK293 Cells
  • Humans
  • MCF-7 Cells
  • Molecular Structure
  • Organoplatinum Compounds / chemistry
  • Organoplatinum Compounds / pharmacology*
  • Photochemotherapy*
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacology*
  • Prodrugs / chemistry
  • Prodrugs / pharmacology*
  • Structure-Activity Relationship

Substances

  • Organoplatinum Compounds
  • Photosensitizing Agents
  • Prodrugs
  • Cisplatin